Adverse events of therapeutic hypothermia were numerous and frequent, necessitating monitoring. Neurological recovery is primarily driven by the type of arrest, the rapidity of ROSC, the time needed to provide and achieve therapeutic hypothermia, the development of seizures or infection, and the use of insulin or epinephrine.

No abstract

INTRODUCTION: Four-factor prothrombin complex concentrate (4F-PCC) is frequently used off-label for reversal of direct oral anticoagulants (DOAC). Recent literature has suggested that 4F-PCC at lower, fixed-doses compared to weight-based dosing for DOAC reversal has achieved similar hemostatic efficacy with no difference in adverse events, repeat doses, length of stay, or mortality. However, the ideal 4F-PCC dose is still uncertain. Institutional guidelines were updated to utilize a fixed dose of 2,000 units for DOAC reversal, for which safety and efficacy were compared to the previous higher weight-based dosing for DOAC reversal. METHODS:This was a retrospective, quasi-experimental study at Carilion Roanoke Memorial Hospital. Patients were included if they received at least one dose of 4F-PCC for DOAC reversal and received the institutional guideline recommendation for treatment at that time. The pre-group,

Background Rituximab is a monoclonal antibody against the CD20 antigen on B-lymphocytes leading to B-cell death and depletion. Patients who receive rituximab and are infected with the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) causing coronavirus disease (COVID-19) may have increased difficultly clearing the virus and be at risk for persistent disease. While the limited literature available is mixed regarding the severity of COVID-19 in patients receiving rituximab, there is minimal literature regarding persistent and relapsing COVID-19 in this patient population. This is a case series of patients with persistent COVID-19 who previously received rituximab. Methods This is a retrospective review of 5 patients admitted between 1/1/2021 and 5/1/2021 to our institution with confirmed COVID-19 and receipt of rituximab for any indication within the previous 12 months. Information regarding hospital readmissions, time course of positive infection, medical management, disease severity, and discharge disposition were collected. Results Five patients, median age of 46, currently or recently on rituximab therapy were admitted a median of 2 times due to persistent, severe COVID-19 (Table 1). Patients received their initial COVID-19 diagnosis a median of 34 days (8-102 days) since their last rituximab administration and had documented SARS-CoV-2 infection a median of 66 days (19-195 days; Figure 1). All 5 patients received remdesivir and corticosteroids over the course of their COVID-19 disease and 2 patients received convalescent plasma therapy 1 and 5 days prior to a positive SARS-CoV-2 antibody IgG. Figure 1. Patient SARS-CoV-2 Infection Course Table 1. Patient Clinical and Therapeutic Data Conclusion Rituximab therapy may be associated with persistent or relapsing COVID-19 disease. Controlled investigations are necessary to evaluate the exact impact anti-CD20 agents have on the course of COVID-19 and whether convalescent plasma or other therapies can prevent relapsing disease. Disclosures All Authors: No reported disclosures